With results from the first Phase III study of its antibiotic lefamulin in community-acquired bacterial pneumonia now under its belt and a second pivotal study due to report in the spring of 2018, Nabriva Therapeutics AG is gearing up for a regulatory filing in the US.
Nabriva announced Sept. 18 that in the LEAP 1 study, lefamulin met the primary endpoint of non-inferiority for early clinical...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
